Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in ...

Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal ...

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 ...

Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

Ttv Dhinakaran

Get all latest & breaking news on Ttv Dhinakaran. Watch videos, top stories and articles on Ttv Dhinakaran at moneycontrol.com.

Mahesh Sharma

Get all latest & breaking news on Mahesh Sharma. Watch videos, top stories and articles on Mahesh Sharma at moneycontrol.com.